

Supplementary Data

SUPPLEMENTARY TABLE S1. SUMMARY OF ANTI-INSULIN ANTIBODY RESPONSE IN PARTICIPANTS USING INSULIN LISPRO BEFORE SORELLA 1 (12 MONTHS) AND SORELLA 2 (6 MONTHS) – AIA POPULATIONS

<i>Participants</i>	<i>SORELLA 1</i>		<i>SORELLA 2</i>	
	<i>SAR-Lis</i> (N=155)	<i>Ly-Lis</i> (N=158)	<i>SAR-Lis</i> (N=130)	<i>Ly-Lis</i> (N=126)
AIA positive at baseline, <i>n</i> (%)	80/155 (51.6)	81/158 (51.3)	31/130 (23.8)	27/126 (21.4)
Median titer (1/dil)	8.00	4.00	4.00	4.00
Q1:Q3	2.00:16.00	2.00:12.00	2.00:8.00	2.00:8.00
Treatment-boosted AIA, <i>n</i> (%)	12/80 (15.0)	19/81 (23.5)	6/31 (19.4)	4/27 (14.8)
Median peak titer ^a (1/dil)	16.00	16.00	8.00	24.00
Q1:Q3	12.00:96.00	8.00:32.00	8.00:32.00	12.00:32.00
AIA negative or missing at baseline, <i>n</i> (%)	75/155 (48.4)	77/158 (48.7)	99/130 (76.2)	99/126 (78.6)
Treatment-induced AIA, <i>n</i> (%)	22/75 (29.3)	17/77 (22.1)	15/99 (15.2)	15/99 (15.2)
Median peak titer ^a (1/dil)	1.00	2.00	4.00	2.00
Q1:Q3	1.00:4.00	1.00:4.00	1.00:32.00	1.00:4.00
Participants with ≥1 positive AIA sample (prevalence) ^b , <i>n</i> (%)	102/155 (65.8)	98/158 (62.0)	46/130 (35.4)	42/126 (33.3)
Patients with treatment-emergent AIA (incidence) ^c , <i>n</i> (%)	34/155 (21.9)	36/158 (22.8)	21/130 (16.2)	19/126 (15.1)

^aMaximal titer measured during the on-treatment period.

^bPrevalence: participants AIA positive at baseline or with treatment-induced AIA.

^cIncidence: participants with treatment-boosted or treatment-induced AIAs (i.e., participants with treatment-emergent AIA). AIA, anti-insulin antibodies; Ly-Lis, insulin lispro; SAR-Lis, SAR342434.